Skip to main content
. 2021 Nov 2;31(8):1293–1307. doi: 10.1093/hmg/ddab317

Figure 9.

Figure 9

Ighmbp2 D564N/D564N mice have respiratory abnormalities that can be improved with ssAAV9-IGHMBP2 delivery. (A-F) PND13 Ighmbp2+/+ mice (green), Ighmbp2D564N/D564N mice (red) and Ighmbp2D564N/D564N ssAAV9-IGHMBP2 injected mice (blue) treated under normoxia and hypoxia + hypercapnia conditions. (A) Respiratory frequency of mice under normoxia and hypoxia + hypercapnia conditions. (B) Minute volume of the three cohorts under normoxia and hypoxia + hypercapnia conditions. (C) Mean inspiratory flow of mice under normoxia and hypoxia + hypercapnia conditions. (D) Tidal volume of the three cohorts under normoxia and hypoxia + hypercapnia conditions. (E) Number of apneas of mice under normoxia and hypoxia + hypercapnia conditions. (F) Percent time spent in erratic breathing of three cohorts under normoxia and hypoxia + hypercapnia conditions. Statistical test used is a two-way ANOVA with a Tukey’s post-hoc test for multiple comparisons. Data bars expressed as mean ± SEM. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, n = 5 animals per cohort; ns = not significant.